IO Biotech, Inc. (IOBTQ)
| Market Cap | 7.20K -100.0% |
| Revenue (ttm) | n/a |
| Net Income | -88.35M |
| EPS | -1.34 |
| Shares Out | 71.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,977 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0020 |
| 52-Week Range | n/a |
| Beta | -0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IO Biotech
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It... [Read more]
Financial Performance
Financial StatementsNews
IO Biotech Provides Corporate Update
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing n...
IO Biotech Announces Exploration of Strategic Alternatives
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free surviv...
IO Biotech Transcript: Piper Sandler 37th Annual Healthcare Conference
Phase III data for IO102-IO103 in melanoma showed meaningful PFS and OS trends with strong safety, though FDA BLA submission was not recommended due to statistical significance. New global trials and EU regulatory discussions are underway, with pipeline expansion and a solid cash runway into 2026.
IO Biotech Transcript: Evercore ISI 8th Annual HealthCONx Conference
The T-win platform demonstrated strong PFS benefits in melanoma, especially in PD-L1 negative patients, though the phase III narrowly missed statistical significance. Plans are underway for a larger, global phase III trial with updated comparators, while pipeline expansion and new trials in other cancers are progressing. Funding strategies include partnerships, especially in Europe.
IO Biotech Announces Participation in Upcoming December Investor Conferences
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
IO Biotech Slides: Corporate Presentation
IO Biotech has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2025.
IO Biotech Transcript: Jefferies London Healthcare Conference 2025
Cylembio's phase III trial in metastatic melanoma narrowly missed statistical significance but showed strong clinical benefit and safety, especially in key subgroups. A new global phase III trial with OPDIVO is planned, while expansion into lung and head and neck cancers and new targets continues.
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou...
IO Biotech Quarterly report: Q3 2025
IO Biotech has published its Q3 2025 quarterly earnings report on November 14, 2025.
IO Biotech Earnings release: Q3 2025
IO Biotech released its Q3 2025 earnings on November 14, 2025, summarizing the period's financial results.
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vac...
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the ...
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster presentati...
IO Biotech Transcript: H.C. Wainwright 27th Annual Global Investment Conference
SilentBio™ showed strong clinical benefit in first-line advanced melanoma, with significant PFS improvement and a clean safety profile. Regulatory submissions are planned for late 2025 (US) and early 2026 (EU), with commercial readiness and pipeline expansion into additional indications.
IO Biotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Lead program IO102-IO103 demonstrated a significant PFS benefit in advanced melanoma with a strong safety profile, and a BLA submission is planned by year-end. Additional updates from head and neck, lung, and neoadjuvant/adjuvant studies are expected, with launch and regulatory preparations underway.
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statist...
IO Biotech Quarterly report: Q2 2025
IO Biotech has published its Q2 2025 quarterly earnings report on August 14, 2025.
IO Biotech Earnings release: Q2 2025
IO Biotech released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
IO Biotech Transcript: Status Update
Cylembio™ plus pembrolizumab improved PFS in first-line advanced melanoma, with strong effects in PD-L1 negative patients and a favorable safety profile. The company plans to discuss these results with the FDA for a potential BLA submission by year-end.
IO Biotech Press release: Status Update
IO Biotech issued a press release on August 11, 2025, disclosing material business information to investors.
IO Biotech's cancer vaccine shows improvement in late-stage study goal
IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late-stage study goal, but was not statistically significant.
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab mon...